Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma

Nozipho Nyakale, Luca Filippi, Colleen Aldous, Mike Sathekge*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)

Abstract

Numerous positron emission tomography (PET) targets for detection and staging of hepatocellular cancer have been developed in recent years. Hepatocellular carcinomas (HCCs) are clinically and pathologically heterogeneous tumours with a high tendency to be aggressive and unresponsive to chemotherapy. Early detection is essential, and the need for an adequate imaging biomarker, which can overcome some of the limitations of conventional radiological imaging, is persistent. Flourine-18 (18F) flourodeoxyglucose (FDG), the most widely used PET radiopharmaceutical, has proven disappointing as a possible staple in the evaluation of HCC. This disappointment had led to experimentation with carious radiotracers, such as the choline derivatives, acetate, and prostate-specific membrane antigen, which appear to complement and/or enhance the role of FDG. In this study, we look at the various PET radiopharmaceuticals that have been used for imaging HCC and the particular pathways that they target in HCC and liver cancers.

Original languageEnglish
Article number1975
JournalCancers
Volume15
Issue number7
DOIs
Publication statusPublished - Apr 2023
Externally publishedYes

Keywords

  • Choline
  • FAPI
  • FDG
  • PET
  • PSMA
  • hepatocellular cancer
  • positron emission tomography
  • yttrium-90

Fingerprint

Dive into the research topics of 'Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Cite this